Real-World Experience with Dolutegravir-Based Two-Drug Regimens

Table 4

Additional data on patients who discontinued DTG 2DR due to virologic failure.

Patients discontinuing DTG 2DR due to virologic failure	N = 4
ART therapy immediately prior to DTG-based 2DR
ATV, RPV, MVC	1
DTG, RPV, NFV	1
EFV, FTC, TDF	1
RAL, EFV, FTC, TDF	1
Second drug included in the DTG 2DR regimen
RPV	2
DRV	1
MVC	1
Response following switch to DTG 2DR
Suppressed prior to switch, became detectable	2
Detectable prior to switch, became suppressed, then rebounded	1
Detectable prior to switch, remained detectable	1

ATV also includes atazanavir boosted with cobicistat or ritonavir. DRV also includes darunavir boosted with cobicistat or ritonavir. 2DR, 2-drug regimen; ATV, atazanavir; DRV, darunavir; DTG, dolutegravir; EFV, efavirenz; FTC, emtricitabine; MVC, maraviroc; NFV, nelfinavir; RAL, raltegravir; RPV, rilpivirine; TDF, tenofovir disoproxil fumarate.